Condition
AMN
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Completed2
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02699190Completed
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT05394064Phase 1TerminatedPrimary
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
NCT05008874TerminatedPrimary
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
NCT03047369Recruiting
The Myelin Disorders Biorepository Project
NCT02961803Phase 2Completed
MD1003-AMN MD1003 in Adrenomyeloneuropathy
Showing all 5 trials